MGC Pharmaceuticals’ “historic” March quarter highlighted by LSE listing and record sales
MGC Pharma became the first medicinal cannabis company to list on the London Stock Exchange, amid record sales of its phytomedicines. CEO Roby Zomer says the company is now ready to capitalise on years of hard work.
MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) (FRA:H5O) has completed arguably its best-ever quarter, with a London Stock Exchange (LSE) listing and record sales highlighting a busy period.
The European-based biopharma company, developing and producing phytocannabinoid-derived medicines, released its March quarterly report this morning.
It also gained Ethics Committee approval for a Phase III trial to evaluate the efficacy and safety of its COVID-19 drug, CimetrA™, expanded its pre-clinical brain cancer study and locked in additional funding.